The Original FDA Approval
In 1985, the U.S. Food and Drug Administration approved dronabinol — synthetic delta-9-THC — under the brand name Marinol for the treatment of chemotherapy-induced nausea and vomiting (CINV) in cancer patients. This made THC one of the earliest cannabis-derived compounds to receive FDA approval, predating the modern medical cannabis movement by decades. The approval was based on clinical trials showing that dronabinol reduced nausea and increased appetite in patients for whom standard antiemetic medications had failed [1].
This is important context that often gets lost in modern cannabis debates: the scientific and regulatory establishment accepted the antiemetic efficacy of THC in 1985. The question since then has not been whether cannabinoids work for nausea — they do — but rather how to optimize delivery, minimize side effects, and determine which patients benefit most.
The Mechanism: How Cannabis Suppresses Nausea
Nausea and vomiting are controlled primarily by the brainstem — specifically the dorsal vagal complex (DVC), which contains dense CB1 receptor expression. The DVC receives signals from the gut, the vestibular system, and higher brain centers, integrating them into the nausea/vomiting response. Cannabinoids acting at CB1 receptors in the DVC suppress this reflex pathway. Additionally, cannabis suppresses the release of substance P and serotonin from gut enterochromaffin cells — the same mechanism targeted by the 5-HT3 receptor antagonists (like ondansetron) used as first-line antiemetics in modern oncology.
The appetite-stimulating ("munchie") effect of THC is mediated by a different mechanism: CB1 activation in the hypothalamus enhances the activity of hunger-promoting neurons and suppresses satiety signals. It also increases the hedonic valuation of food — making food smell better and taste more rewarding — via CB1 in the nucleus accumbens and olfactory bulb.
AIDS Wasting: The Beal 1995 Trial
The second FDA approval for dronabinol came in 1992 for AIDS-related anorexia (appetite loss and wasting syndrome). This followed clinical evidence including a pivotal 1995 trial by Beal and colleagues in the Journal of AIDS, which randomized 139 HIV patients with appetite loss to dronabinol or placebo for six weeks. The dronabinol group showed significant improvements in appetite (38% vs. 8% placebo), mood, and nausea, with modest but meaningful weight stabilization [2].
"In the era before effective antiretroviral therapy, wasting was a terminal feature of AIDS. Dronabinol provided real palliation — not a cure, but a meaningful improvement in quality of life and, in some patients, the ability to maintain weight long enough to survive to newer treatments."
— Dr. Donald Abrams, Professor of Clinical Medicine, UCSF, cannabis and HIV/oncology researcher
Cannabis vs. Dronabinol in Cancer Care
A fundamental question is whether inhaled or oral whole-plant cannabis outperforms the approved pharmaceutical dronabinol for cancer patients. A 2006 trial by Strasser and colleagues in the Journal of Clinical Oncology compared a standardized cannabis extract (containing both THC and CBD), dronabinol (THC alone), and placebo in 243 cancer patients with anorexia. Results were surprising: cannabis extract did not significantly outperform dronabinol, and neither was dramatically better than placebo on the primary appetite endpoint. However, secondary measures showed modest improvements in quality of life and food enjoyment in the cannabis extract group [3].
Key Research Findings
- FDA approved synthetic THC (dronabinol/Marinol) for chemotherapy nausea in 1985 — one of the earliest cannabis-based drug approvals
- Dronabinol approved for AIDS anorexia in 1992; 38% vs. 8% placebo improvement in appetite (Beal et al., 1995)
- CB1 receptors in the dorsal vagal complex directly suppress nausea/vomiting reflex pathways
- Cannabis extract vs. dronabinol comparison showed modest differences in a 243-patient RCT (Strasser et al., 2006)
- Whiting et al. 2015 JAMA systematic review found moderate-quality evidence for cannabinoids vs. placebo for nausea
- Inhaled cannabis offers faster onset antiemetic effect — clinically relevant for acute post-chemotherapy nausea
Practical Considerations for Oncology Patients
Modern oncology practice has access to highly effective antiemetics — the 5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant), and steroids used in combination can control CINV in the majority of patients. Cannabis is generally not first-line in this context. However, for patients who have breakthrough nausea despite standard regimens, or who cannot tolerate conventional antiemetics, cannabis provides a meaningful option with a robust evidence base and decades of clinical use.
For appetite stimulation in cancer and AIDS patients, the evidence supports modest benefit — not dramatic reversal of cachexia (the complex metabolic wasting syndrome), but meaningful improvement in appetite, food enjoyment, and quality of life. For patients in palliative care settings where comfort and quality of life are the primary goals, this is clinically significant even if the effect size is modest.
The 40-year clinical history of dronabinol provides something few cannabis-adjacent topics can claim: genuine, replicated, FDA-reviewed evidence of efficacy. Whatever debates surround other cannabis applications, the antiemetic and appetite-stimulating effects of THC rest on a solid foundation of clinical trial data.